Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System
暂无分享,去创建一个
Yake Lou | Yinghui Wang | Zhe Wang | Min-Xue Sun | Qi Wang | Xiaonan Li | Yuehui Wang | Minxue Sun
[1] Yake Lou,et al. Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China , 2022, American Journal of Cardiovascular Drugs.
[2] D. Stub,et al. Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction , 2022, Circulation. Cardiovascular quality and outcomes.
[3] Xinyue Dong,et al. Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting , 2022, PharmacoEconomics.
[4] Jun Xie,et al. Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China , 2022, Frontiers in Cardiovascular Medicine.
[5] Akshay S. Desai,et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. , 2022, The New England journal of medicine.
[6] A. Cai,et al. Clinical characteristics and 1‐year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association Database‐Heart Failure Center Registry , 2022, European journal of heart failure.
[7] Yake Lou,et al. Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials , 2022, Frontiers in Public Health.
[8] Report on Cardiovascular Health and Diseases in China 2021: An Updated Summary. , 2022, Biomedical and environmental sciences : BES.
[9] R. Krittayaphong,et al. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction , 2022, American Journal of Cardiovascular Drugs.
[10] Jin Liu,et al. Five‐year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort , 2022, ESC heart failure.
[11] M. Drummond,et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations , 2022, BMC Medicine.
[12] S. Staniszewska,et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations , 2022, PharmacoEconomics.
[13] G. Sinagra,et al. [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.
[14] C. Strong,et al. Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region , 2021, Frontiers in Cardiovascular Medicine.
[15] C. Strong,et al. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region , 2021, Cardiovascular Diabetology.
[16] R. Krittayaphong,et al. Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand , 2021, Clinical Drug Investigation.
[17] J. McMurray,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.
[18] P. Ponikowski,et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.
[19] Xiaodong Lin,et al. Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective , 2021, Journal of Thoracic Disease.
[20] M. Metra,et al. Heart failure in the last year: progress and perspective , 2020, ESC heart failure.
[21] Jian Zhang,et al. Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China , 2020, ESC heart failure.
[22] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.
[23] G. Filippatos,et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.
[24] S. Solomon,et al. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. , 2020, JAMA cardiology.
[25] Benhong Zhou,et al. Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China , 2020, Frontiers in Pharmacology.
[26] F. Rutten,et al. Epidemiology of heart failure , 2020, European journal of heart failure.
[27] M. Metra,et al. Corrigendum to ‘Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012–2015’ [Eur J Heart Fail 2019;21:1329–1337] , 2020, European journal of heart failure.
[28] Zengwu Wang,et al. Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012–2015 , 2019, European journal of heart failure.
[29] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[30] Akshay S. Desai,et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.
[31] Samprit Banerjee,et al. Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES) , 2019, BMC Cardiovascular Disorders.
[32] G. Fonarow,et al. Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry. , 2017, Journal of cardiac failure.
[33] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[34] M. Herdman,et al. A comparison of the scaling properties of the English, Spanish, French, and Chinese EQ-5D descriptive systems , 2013, Quality of Life Research.
[35] S. Silver,et al. Heart Failure , 1937, The New England journal of medicine.